Literature DB >> 11792957

Over expression of clusterin is an independent prognostic factor for nonpapillary renal cell carcinoma.

Hideaki Miyake1, Shoji Hara, Soichi Arakawa, Sadao Kamidono, Isao Hara.   

Abstract

PURPOSE: Recent studies have revealed the powerful anti-apoptotic activity of clusterin in several types of malignant tumors. However, the significance of clusterin expression in human renal cell carcinoma has not been well characterized. We determined whether the expression level of clusterin in nonpapillary renal cell carcinoma may be used as predictor of tumor progression and prognosis.
MATERIALS AND METHODS: Total RNA was extracted from 93 nonpapillary renal cell carcinomas obtained at surgery and expression levels of clusterin messenger (m)RNA in these specimens were measured by Northern blot analysis. Findings were analyzed with respect to several clinicopathological factors.
RESULTS: There were 48 cases (52%) with strong clusterin mRNA expression and 45 (48%) in which it was weak or nonexistent. The expression level of clusterin mRNA did not significantly correlate with patient gender, age, tumor grade or size, or histological cell type, whereas pathological stage and the incidence of tumor recurrence were closely associated with clusterin expression (p <0.005 and <0.01, respectively). The recurrence-free and overall survival rates in patients with strong clusterin expression were significantly lower than in those with weak or no expression (p <0.05). Furthermore, multivariate analyses revealed that strong expression of clusterin was an independent predictor of tumor recurrence and overall survival (p <0.05).
CONCLUSIONS: These findings suggest that the over expression of clusterin may be a useful prognostic parameter in patients with nonpapillary renal cell carcinoma after radical nephrectomy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11792957     DOI: 10.1097/00005392-200202000-00069

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

1.  Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein.

Authors:  Eijiro Nakamura; Paula Abreu-e-Lima; Yasuo Awakura; Takahiro Inoue; Toshiyuki Kamoto; Osamu Ogawa; Hirokazu Kotani; Toshiaki Manabe; Guo-Jun Zhang; Keiichi Kondo; Vānia Nosé; William G Kaelin
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

2.  Screening and cloning for proteins transactivated by the PS1TP5 protein of hepatitis B virus: a suppression subtractive hybridization study.

Authors:  Jian-Kang Zhang; Long-Feng Zhao; Jun Cheng; Jiang Guo; Dan-Qiong Wang; Yuan Hong; Yu Mao
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

3.  Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.

Authors:  Amina Zoubeidi; Kim Chi; Martin Gleave
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

4.  Tumor biomarker glycoproteins in the seminal plasma of healthy human males are endogenous ligands for DC-SIGN.

Authors:  Gary F Clark; Paola Grassi; Poh-Choo Pang; Maria Panico; David Lafrenz; Erma Z Drobnis; Michael R Baldwin; Howard R Morris; Stuart M Haslam; Sophia Schedin-Weiss; Wei Sun; Anne Dell
Journal:  Mol Cell Proteomics       Date:  2011-10-10       Impact factor: 5.911

Review 5.  Classical pathology versus molecular pathology in renal cell carcinoma.

Authors:  Peggy Soung Sullivan; JianYu Rao; Liang Cheng; Richard J Cote
Journal:  Curr Urol Rep       Date:  2007-01       Impact factor: 3.092

6.  Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model.

Authors:  Masatomo Nishikawa; Hideaki Miyake; Martin Gleave; Masato Fujisawa
Journal:  Target Oncol       Date:  2017-02       Impact factor: 4.493

7.  Clusterin expression inversely correlates with chemosensitivity and predicts poor survival in patients with locally advanced cervical cancer treated with cisplatin-based neoadjuvant chemotherapy and radical hysterectomy.

Authors:  Hidemichi Watari; Tatsuya Kanuma; Yoko Ohta; Mohamed Kamel Hassan; Takashi Mitamura; Masayoshi Hosaka; Takashi Minegishi; Noriaki Sakuragi
Journal:  Pathol Oncol Res       Date:  2010-01-08       Impact factor: 3.201

8.  Multidimensional liquid chromatography platform for profiling alterations of clusterin N-glycosylation in the plasma of patients with renal cell carcinoma.

Authors:  Fateme Tousi; Jonathan Bones; Othon Iliopoulos; William S Hancock; Marina Hincapie
Journal:  J Chromatogr A       Date:  2012-07-28       Impact factor: 4.759

9.  Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer.

Authors:  Dong Choon Park; Seung Geun Yeo; Mark R Wilson; Justin J Yerbury; Joseph Kwong; William R Welch; Yang Kyu Choi; Michael J Birrer; Samuel C Mok; Kwong-Kwok Wong
Journal:  Neoplasia       Date:  2008-09       Impact factor: 5.715

10.  Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel.

Authors:  Mohamed K Hassan; Hidemichi Watari; Yimin Han; Takashi Mitamura; Masayoshi Hosaka; Lei Wang; Shinya Tanaka; Noriaki Sakuragi
Journal:  J Exp Clin Cancer Res       Date:  2011-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.